Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson’s Disease: Inhibition of T Helper 17 Cell Differentiation and Regulation of Immune Balance Towards a Regulatory T Cell Phenotype

References

• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184. doi:10.1136/jnnp.55.3.1811564476
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912. doi:10.1016/S0140-6736(14)61393-325904081
   PubMed Web of Science ®Google Scholar
• Brochard V, Combadière B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–192. doi:10.1172/JCI3647019104149
   PubMed Web of Science ®Google Scholar
• Saunders JAH, Estes KA, Kosloski LM, et al. CD4+ regulatory and effector/memory t cell subsets profile motor dysfunction in Parkinson’s disease. J Neuroimmune Pharmacol. 2012;7(4):927–938. doi:10.1007/s11481-012-9402-z23054369
   PubMed Web of Science ®Google Scholar
• Cen L, Yang C, Huang S, et al. Peripheral lymphocyte subsets as a marker of Parkinson’s disease in a Chinese population. Neurosci Bull. 2017;33(5):493–500. doi:10.1007/s12264-017-0163-928791571
   PubMed Web of Science ®Google Scholar
• Park J, Lee J-W, Cooper SC, Broxmeyer HE, Cannon JR, Kim CH. Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. J Leukoc Biol. 2017;102(4):1093–1102. doi:10.1189/jlb.1A0417-147RR28751472
   PubMed Web of Science ®Google Scholar
• Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state and disease. Nat Neurosci. 2017;20(2):136–144. doi:10.1038/nn.447528092660
   PubMed Web of Science ®Google Scholar
• Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546(7660):656–661. doi:10.1038/nature2281528636593
   PubMed Web of Science ®Google Scholar
• Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 lymphocytes and IL-17 contribute to Parkinson’s disease? A systematic review of available evidence. Front Neurol. 2019;10.30733702
   PubMed Web of Science ®Google Scholar
• Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson’s disease. Cell Stem Cell. 2018;23(1):123–131.e6. doi:10.1016/j.stem.2018.06.01529979986
   PubMed Web of Science ®Google Scholar
• Liu Z, Qiu A-W, Huang Y, et al. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson’s disease. Brain Behav Immun. 2019;81:630–645. doi:10.1016/j.bbi.2019.07.02631351185
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Hutter JAL, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–2271. doi:10.4049/jimmunol.090185220118279
   PubMed Web of Science ®Google Scholar
• Liu Z, Huang Y, Cao -B-B, Qiu Y-H, Peng Y-P. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of Parkinson’s disease. Mol Neurobiol. 2017;54(10):7762–7776. doi:10.1007/s12035-016-0249-927844285
   PubMed Web of Science ®Google Scholar
• Dutta D, Kundu M, Mondal S, et al. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson’s disease. Neurobiol Dis. 2019;132:104575. doi:10.1016/j.nbd.2019.10457531445159
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Mosley RL, Gendelman HE. Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J Proteome Res. 2009;8(7):3497–3511. doi:10.1021/pr900161419432400
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu Z, Cao -B-B, Qiu Y-H, Peng Y-P. Treg cells protect dopaminergic neurons against MPP+ neurotoxicity via CD47-SIRPA interaction. Cell Physiol Biochem. 2017;41(3):1240–1254. doi:10.1159/00046438828268219
   PubMedGoogle Scholar
• Chen Y, Qi B, Xu W, et al. Clinical correlation of peripheral CD4+‑cell sub‑sets, their imbalance and Parkinson’s disease. Mol Med Rep. 2015;12(4):6105–6111. doi:10.3892/mmr.2015.413626239429
   PubMed Web of Science ®Google Scholar
• Gendelman HE, Zhang Y, Santamaria P, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind Phase 1 clinical Parkinson’s disease trial. NPJ Parkinsons Dis. 2017;3(1):10. doi:10.1038/s41531-017-0013-528649610
   PubMed Web of Science ®Google Scholar
• Duffy SS, Keating BA, Perera CJ, Moalem-Taylor G. The role of regulatory T cells in nervous system pathologies. J Neurosci Res. 2018;96(6):951–968. doi:10.1002/jnr.2407328488363
   PubMed Web of Science ®Google Scholar
• Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, et al. Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs: other regulatory populations are also involved. J Neuroinflammation. 2019;16(1):212. doi:10.1186/s12974-019-1606-131711508
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28(1):445–489. doi:10.1146/annurev-immunol-030409-10121220192806
   PubMed Web of Science ®Google Scholar
• Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140(6):845–858. doi:10.1016/j.cell.2010.02.02120303875
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD. Interplay between the T H 17 and T Reg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol. 2009;9(12):883–889. doi:10.1038/nri266019935807
   PubMed Web of Science ®Google Scholar
• Chang K-A, Lee J-H, Suh Y-H. Therapeutic potential of human adipose-derived stem cells in neurological disorders. J Pharmacol Sci. 2014;126(4):293–301. doi:10.1254/jphs.14R10CP25409785
   PubMed Web of Science ®Google Scholar
• Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493–507. doi:10.1038/s41581-018-0023-529895977
   PubMed Web of Science ®Google Scholar
• Darlington PJ, Boivin M-N, Renoux C, et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Ann Neurol. 2010;68(4):540–545. doi:10.1002/ana.2206520661924
   PubMed Web of Science ®Google Scholar
• Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a Phase 3 randomised, double-blind controlled trial. Lancet. 2016;388(10051):1281–1290. doi:10.1016/S0140-6736(16)31203-X27477896
   PubMed Web of Science ®Google Scholar
• Álvaro-Gracia JM, Jover JA, García-Vicuña R, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196–202. doi:10.1136/annrheumdis-2015-20891827269294
   PubMed Web of Science ®Google Scholar
• Wang D, Huang S, Yuan X, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423–431. doi:10.1038/cmi.2015.8926435067
   PubMed Web of Science ®Google Scholar
• Prots I, Winner B. Th17 cells: a promising therapeutic target for Parkinson’s disease? Expert Opin Ther Targets. 2019;23(4):309–314. doi:10.1080/14728222.2019.159033630871383
   PubMed Web of Science ®Google Scholar
• Xiao-bin LIN. Adipose tissue-derived stem cells mediated immunosuppression on Th17 in multiple sclerosis. Chin J Pathophysiol. 2016;32(1):51–57.
   Google Scholar
• Jia L, Chen Y, Chen Z, et al. Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice. Sci Rep. 2017;7(1):42695. doi:10.1038/srep4269528198408
   PubMed Web of Science ®Google Scholar
• Cao W, Yang Y, Wang Z, et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity. 2011;35(2):273–284. doi:10.1016/j.immuni.2011.06.01121835648
   PubMed Web of Science ®Google Scholar
• Janssens K, Van den Haute C, Baekelandt V, et al. Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis. Brain Behav Immun. 2015;45:180–188. doi:10.1016/j.bbi.2014.11.01025514345
   PubMed Web of Science ®Google Scholar
• Athauda D, Foltynie T. The ongoing pursuit of neuroprotective therapies in Parkinson disease. Nat Rev Neurol. 2015;11(1):25–40. doi:10.1038/nrneurol.2014.22625447485
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Mov Disord. 2015;30(11):1442–1450. doi:10.1002/mds.2635426208210
   PubMed Web of Science ®Google Scholar
• Schutt CR, Gendelman HE, Mosley RL. Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson’s disease. Mol Neurodegener. 2018;13(1):26. doi:10.1186/s13024-018-0255-729783988
   PubMed Web of Science ®Google Scholar
• Peters A, Pitcher LA, Sullivan JM, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011;35(6):986–996. doi:10.1016/j.immuni.2011.10.01522177922
   PubMed Web of Science ®Google Scholar
• Ghannam S, Pène J, Moquet-Torcy G, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185(1):302–312. doi:10.4049/jimmunol.090200720511548
   PubMed Web of Science ®Google Scholar
• Kwon M-S, Noh M-Y, Oh K-W, et al. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. J Neurochem. 2014;131(2):206–218. doi:10.1111/jnc.1281424995608
   PubMed Web of Science ®Google Scholar
• Baharlou R, Ahmadi-Vasmehjani A, Faraji F, et al. Human adipose tissue-derived mesenchymal stem cells in rheumatoid arthritis: regulatory effects on peripheral blood mononuclear cells activation. Int Immunopharmacol. 2017;47:59–69. doi:10.1016/j.intimp.2017.03.01628364628
   PubMed Web of Science ®Google Scholar
• Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol. 2011;6(1):457–478. doi:10.1146/annurev-pathol-011110-13023021073342
   PubMed Web of Science ®Google Scholar
• Metcalfe SM. LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun. 2011;12(3):157–168. doi:10.1038/gene.2011.921368774
   PubMed Web of Science ®Google Scholar
• Gao W, Thompson L, Zhou Q, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. Cell Cycle. 2009;8(9):1444–1450. doi:10.4161/cc.8.9.834819342884
   PubMed Web of Science ®Google Scholar
• Bi Y, Lin X, Liang H, et al. Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson’s disease: Inhibit T Helper 17 Cell Differentiation and Regulate Immune Balance Towards a Regulatory T Cell Phenotype. 2020.
   Google Scholar